UPDATE: Citi Upgrades Novavax (NVAX) to Buy
Tweet
Share
E-mailGet Alerts NVAX Hot Sheet
Price: $9.43 +6.43%
Rating Summary:
10 Buy, 3 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 9 | New: 13
Rating Summary:
10 Buy, 3 Hold, 5 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 8 | Down: 9 | New: 13
Join SI Premium – FREE
(Updated - October 31, 2017 6:21 AM EDT)
(updated to add analyst comment)
Citi upgraded Novavax (NASDAQ: NVAX) from Neutral to Buy with a price target of $1.60 (from $1.10).
Analyst Joel Beatty believes the market is overlooking the NT flu vaccine catalysts which he believes represents a strong market opportunity as superior flu vaccines are in demand.
For an analyst ratings summary and ratings history on Novavax click here. For more ratings news on Novavax click here.
Shares of Novavax closed at $1.02 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Calumet Specialty Products Partners (CLMT) PT Raised to $47 at UBS
- Palo Alto Networks (PANW) PT Raised to $384 at JPMorgan Ahead of Q4 Results
- BXP Inc. (BXP) PT Raised to $70 at UBS as Earnings Outlook Accelerates
Create E-mail Alert Related Categories
Analyst Comments, Analyst PT Change, Hot Upgrades, UpgradesRelated Entities
CitiSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
